Abstract Introduction MET exon 14 (METex14) skipping mutations occur in 3–4% of non-
small-cell lung cancer (NSCLC) cases. Currently, four oral MET tyrosine kinase inhibitors …

Lung cancer is one of the most common cancers in the population and is characterized by
non-specific symptoms that delay the diagnosis and reduce the effectiveness of oncological …

The etiological role of NSD2 enzymatic activity in solid tumors is unclear. Here we show that
NSD2, via H3K36me2 catalysis, cooperates with oncogenic KRAS signaling to drive lung …

Osimertinib (OB) is a third-generation irreversible tyrosine kinase inhibitor targeting the
epidermal growth factor receptor (EGFR), overexpressed in non-small cell lung cancer …

The advent of precision medicine has changed the landscape of oncologic biomarkers, drug
discovery, drug development, and, more importantly, outcomes for patients with cancer …

In this study, we aim to investigate the therapeutic effect and safety of ALK inhibitor in ALK-
positive lung cancer patients. 59 patients with ALK-positive lung cancer from August 2013 to …

Nanomedicine is an interdisciplinary field where nanostructured objects are applied to treat
or diagnose disease. Nanoparticles (NPs) are a special class of materials at nanometric …

​ Background Immunotherapy for lung cancer has been a hot research area for years. This
bibliometric analysis aims to present the research trends on lung cancer immunotherapy …

Background The association between driver genes and the incidence of thromboembolic
events (TEs) in patients diagnosed with non-small-cell lung cancer (NSCLC) needs to be …

Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …